Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
pd [2018/11/18 11:25]
sflitman [Parkinson's Disease]
pd [2020/06/19 13:48]
sflitman [Parkinson's Disease]
Line 5: Line 5:
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^  Comparator  ^  Duration  ^  Open Label Extension  ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^  Comparator  ^  Duration  ^  Open Label Extension  ^
 | Mild to Moderate Parkinson's Disease | Delayed Release Carbidopa/Levodopa |  III  |  No    50% get plain CD/LD  |  24 weeks  |  9 months  | | Mild to Moderate Parkinson's Disease | Delayed Release Carbidopa/Levodopa |  III  |  No    50% get plain CD/LD  |  24 weeks  |  9 months  |
 +| Moderate to Advanced Parkinson's Disease | Carbidopa/Levodopa Continuous Subdermal infusion |  III  |  Yes  |  Sham infusion  | 12 months  |  Yes  |
 +| Moderate to Advanced Parkinson's Disease | Carbidopa/Levodopa Continuous Subdermal infusion |  III  |  Yes  |  Sham infusion  | 12 months  |  Yes  |
 +| Dyskinesias in Parkinson's Disease | Novel oral agent |  II  |  Yes  |  33%  |  1 year  |  No  |
 +| Dyskinesias in Parkinson's Disease | Novel oral agent |  II  |  Yes  |  33%  |  1 year  |  No  |
  
 <html><!-- <html><!--
-| Mild to Moderate Parkinson's Disease | Carbidopa/Levodopa Accordion pill |  III  |  Yes  |  33%  |  12 weeks  |  No  | 
-| Moderate to Advanced Parkinson's Disease | Carbidopa/Levodopa Continuous Subdermal infusion |  II  |  No  |  No  | 12 months  |  Yes  | 
 | Moderate to Severe Parkinson's Disease | Oral adenosine-2a antagonist |  III  |  Yes  |  33%  |  12 weeks  |  Yes  | | Moderate to Severe Parkinson's Disease | Oral adenosine-2a antagonist |  III  |  Yes  |  33%  |  12 weeks  |  Yes  |
 --></html> --></html>
Print/export
QR Code
QR Code pd (generated for current page)